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Objectives. This study was undertaken to determine whether
lipoprotein(a) [Lp(a)] is an independent risk factor for ischemic
heart disease (IHD) and to establish the relation of Lp(a) to the
other lipid fractions.
Background. Several, but not all, studies have shown that
elevated Lp(a) concentrations may be associated with IHD; very
few have been prospective.
Methods. A 5-year prospective follow-up study was conducted in
2,156 French Canadian men 47 to 76 years old, without clinical
evidence of IHD. Lipid measurements obtained at baseline in-
cluded total cholesterol, low density lipoprotein (LDL) choles-
terol, high density lipoprotein (HDL) cholesterol, apoprotein B
and Lp(a). During the follow-up period, there were 116 first IHD
events (myocardial infarction, angina, death). Adjusted propor-
tional hazards models were used to estimate the relative risk for
the different variables. The cohort was also classified according to
Lp(a) levels and other lipid risk factor tertiles to evaluate the
relation of elevated Lp(a) levels to these risk factors. A cutoff value
of 30 mg/dl was used for Lp(a). Risk ratios were calculated using
the group with low Lp(a) levels and the first tertile of lipid
measures as a reference.
Results. Lp(a) was not an independent risk factor for IHD but
seemed to increase the deleterious effects of mildly elevated LDL
cholesterol and elevated total cholesterol and apoprotein B levels
and seemed to counteract the beneficial effects associated with
elevated HDL cholesterol levels.
Conclusions. In this cohort, Lp(a) was not an independent risk
factor for IHD but appeared to increase the risk associated with
other lipid risk factors.
(J Am Coll Cardiol 1998;31:519–25)
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Several studies have shown that elevated lipoprotein(a)
[Lp(a)] concentrations are associated with ischemic heart
disease (IHD) (1–6), restenosis after percutaneous translumi-
nal coronary angioplasty (PTCA) (7,8), coronary artery disease
progression (9,10), cerebrovascular disease (11–13) and inter-
mittent claudication (14–16). Most of the currently available
evidence on Lp(a) as risk factor for IHD is derived from
case-control studies (1,2,5,17,18) and a few prospective
population-based studies: one from Iceland reported by Sig-
urdsson et al. (3), the Go¨ttingen Risk Incidence and Preva-
lence Study (GRIPS) (19) and the report of Bostom et al. (20)
in a group of men from the Framingham cohort. However, the
potential relation between Lp(a) and IHD has been ques-
tioned by many case-control studies (2,17,21,22) and the
cross-sectional Finland Cardiovascular Risk (FINRISK) Hae-
mostasis Study (23), all of which failed to identify a similar
relation. Thus, there is some controversy as to the role of Lp(a)
as an independent risk factor for IHD. It is possible that Lp(a)
may contribute to IHD risk through synergistic mechanisms
with low density lipoprotein (LDL) cholesterol, as suggested by
a study of familial hypercholesterolemia (24) and the GRIPS
trial (19). The present study sought to examine whether Lp(a)
is an independent risk factor for, and may contribute to the
effect of other lipid fractions in IHD, in 2,156 French Canadian
men prospectively followed up from 1985 until 1990.
Methods
Patients, risk factor evaluations and follow-up. The study
was approved by the ethics committee of the Faculty of
Medicine, Laval University, Ste-Foy, Quebec, Canada. The
random selection of participants and screening methods have
been previously described (25). Briefly, 4,637 men 35 to 64
years old in 1973 and living in Quebec City suburbs partici-
pated in the Quebec Cardiovascular Study. Among these 4,637
men, 252 were excluded because they had coronary or vascular
disease before entry into the study. The initial screening was
conducted from December 1973 to July 1974. The cohort was
evaluated approximately every 5 years. In 1985, cohort partic-
ipants were invited to participate in an evaluation that included
a complete questionnaire on cardiovascular diseases, diabetes,
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smoking and medication, blood pressure, height and weight
measurements, an electrocardiogram as well as a fasting
plasma lipid profile. Rest blood pressure measurements were
performed after a 5-min rest in a sitting position using phases
1 and 5 of the Korotkoff sounds for systolic and diastolic blood
pressure, respectively. The mean of two blood pressure mea-
surements taken 5 min apart was used in the analyses. Diabetes
was considered only if men were treated with hypoglycemic
agents. Smoking status was defined as follows: 1) nonsmokers
(never smoked); 2) ex-smokers (those who discontinued their
habit at least 1 year before evaluation); 3) pipe or cigar
smokers, or both; 4) smokers consuming 1 to 20 cigarettes/day;
and 5) smokers of $21 cigarettes/day. In 1985, fasting blood
samples could be obtained in 2,261 of the 3,747 living men
without IHD. Among the 1,486 men who did not have lipid
determinations, 1,025 (69%) refused the evaluation or were
evaluated at their home clinic; 356 (24%) were excluded
because they were not in a fasting state; and 105 (7%) could
not be located in 1985. Nevertheless, the age distribution of the
2,261 men included in the study was representative of the
original cohort, and the event rate was similar to that found in
men who had remained event free until 1985. In 1990, all men
were contacted by mail and invited to answer a short standard-
ized questionnaire on smoking habits, cardiovascular diseases,
medication and diabetes. Telephone calls were made to par-
ticipants who did not answer a second letter and, if unsuccess-
ful, to a close family member. At the end of the follow-up
period (September 1, 1990), mortality and morbidity data had
been obtained for 99% and 96% of the participants, respec-
tively.
Clinical evaluation of IHD. The diagnosis of IHD events
was based on typical description of symptoms, ECG findings
and biochemical analyses or autopsy results. Angina was diag-
nosed solely on the basis of typical retrosternal squeezing or
heaviness discomfort ,5 min in duration, brought on by
exertion and relieved by rest or administration of nitroglycerin,
or both, and was always confirmed by a cardiologist of the
study group. Coronary insufficiency was considered when typi-
cal chest pain was prolonged from 5 to 15 min and was
accompanied by ECG changes. Myocardial infarction (MI) was
diagnosed according to ECG criteria 1.1 of the Minnesota code
or in the presence of two of the following three criteria:
prolonged typical chest pain, ischemic ECG changes or creat-
ine kinase elevation twice above the upper normal limit. MI
was considered fatal when death occurred within 28 days of the
initial event. Coronary deaths were diagnosed according to the
autopsy findings or by exclusion of other causes. Diagnoses
were completed from hospital files by trained health profes-
sionals and were confirmed by a cardiologist (G.R.D.) unaware
of the risk factor profile of the participants. Informed consent
for review of hospital files was obtained from the participants
or from the hospital authorities for participants who had died.
For the participants who died outside the hospital, the cause of
death was obtained from the Provincial Death Registry, and a
cardiologist from the study interviewed a member of the
immediate family as to the circumstances of death.
Lipoprotein determinations. All lipoprotein determina-
tions were made after an overnight fast. Laboratory determi-
nations were standardized using control sera obtained from the
Centers for Disease Control and Prevention (Atlanta, Geor-
gia). Blood samples were obtained by venipuncture into
EDTA-containing tubes. Blood samples were centrifuged at
low speed to obtain plasma, and aliquots were stored at 280°C.
Total cholesterol was determined from fresh plasma samples
after extraction in isopropanol using an Auto-Analyzer II
(Technicon Instruments Inc.). High density lipoprotein (HDL)
cholesterol levels were obtained by heparin-manganese precip-
itation (26–28). Except for patients with dysbetalipoproteine-
mia or those in whom triglyceride levels were .4.5 mmol/liter,
LDL levels were calculated as described by Friedewald et al.
(29). The electroimmunoassay of Laurell (30) was used to
quantitate plasma apolipoprotein B levels. Plasma Lp(a) con-
centrations were measured in 1992 from samples frozen in
1985 that were thawed to 4°C. Lp(a) concentrations were
measured by enzyme-linked immunosorbent assay (ELISA)
using kits obtained from Biopool (Umeå, Sweden).
Statistical analyses. Follow-up duration in person-years
was calculated according to the participation of each subject
from the 1985 evaluation until the last contact or first IHD
event. Differences in mean values for risk factors were tested
by analysis of variance, and differences in smoking and diabe-
tes rates were tested by chi-square analysis.
Adjusted risk ratios of IHD were calculated as the adjusted
rates for tertiles 2 and 3, divided by the corresponding rate for
tertile 1 using a Cox proportional hazards model (31). For
smokers and ex-smokers, the relative risk was determined by
dividing their rates of IHD by the rate of those who never
smoked. In these analyses, two models were used. In both
instances, age, systolic blood pressure, smoking status and
Lp(a) levels were included. In model 1, total cholesterol was
also entered. In model 2, total cholesterol was replaced by
LDL and HDL cholesterol. A stepwise discriminant analysis
was also performed for each model to further evaluate the
effect of Lp(a) on IHD. These analyses were repeated in a
subset of men in whom angina and coronary insufficiency as a
first event were excluded.
Finally, to evaluate any synergy between Lp(a) and signifi-
cant lipid risk factors, subjects were classified into groups using
lipid value tertiles and either high ($30 mg/dl) or low (,30
mg/dl) Lp(a) levels. Each of the first tertiles of lipid risk factor
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
GRIPS 5 Go¨ttingen Risk Incidence and Prevalence Study
HDL 5 high density lipoprotein
IHD 5 ischemic heart disease
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
MI 5 myocardial infarction
NCEP 5 National Cholesterol Education Program
PTCA 5 percutaneous transluminal coronary angioplasty
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distribution combined with low (,30 mg/dl) Lp(a) levels was
assigned a relative risk of 1. Subjects in the other groups [first
tertile and high Lp(a); second tertile and low Lp(a); second
tertile and high Lp(a); third tertile and low Lp(a); third tertile
and high Lp(a)] were compared with the reference group using
a Cox proportional hazards model to evaluate potential inter-
actions between Lp(a) and other risk factors.
Results
During the follow-up period, there were 116 first IHD
events: 51 men had an MI; 41 experienced angina; 9 had
coronary insufficiency; and 15 died. Baseline characteristics of
men with and without IHD are summarized in Table 1. Fewer
than 5% of men in either group were using hypolipidemic
drugs in 1985. Men with IHD were older, smoked more, had a
higher systolic blood pressure and prevalence of diabetes as
well as elevated total cholesterol, LDL cholesterol, apoprotein
B and Lp(a) levels and low HDL-cholesterol levels. Figure 1
shows the distribution of Lp(a) levels in men with and without
IHD.
Lp(a) levels correlated positively with total cholesterol,
LDL cholesterol and apoprotein B (Table 2). In both models,
age, systolic blood pressure and smoking were found to
correlate significantly with IHD. However, Lp(a) was never
found to be an independent risk factor for IHD (Table 3). In
model 1, the highest tertile of total cholesterol was associated
with an increased IHD risk. In model 2, cholesterol within
lipoprotein fractions was also related to IHD. LDL cholesterol
in the two highest tertiles was associated with an increased
IHD risk, whereas the highest HDL cholesterol tertile had a
protective effect. Stepwise discriminant analyses of each model
yielded essentially similar results (Table 4). In view of the
distribution of Lp(a) values in the cohort, a logarithmic
transformation of Lp(a) data was performed to evaluate its
potential as a risk factor. Cutoff values for high and low Lp(a)
(25, 30, 35 and 75 mg/dl) were also used to treat it as a
dichotomic variable in proportional hazards and stepwise
analyses. None of these approaches could reveal a significant
impact of Lp(a) on IHD. Finally, the multivariate analyses
(Cox proportional hazards and stepwise discriminant) were
done using data from patients who experienced MI or coronary
death. These analyses yielded similar results: age, systolic
blood pressure and cholesterol levels were significant and
independent risk factors, whereas Lp(a) was not.
Table 5 examines the synergy between known lipid risk
factors and Lp(a). As shown in Table 3, the last tertile of the
cholesterol distribution was associated with an increased risk
of IHD. However, this risk was further increased by the
presence of Lp(a) concentrations $30 mg/dl. In Table 3, the
second tertile of the LDL cholesterol distribution was associ-
ated with an increased risk of IHD. The data in Table 5 show
that this risk was associated with the presence of increased
Lp(a) levels. It also appeared that the significant risk found in
Figure 1. Frequency distribution of Lp(a) levels of subjects with (solid
bars) and without (open bars) IHD.
Table 1. Baseline Characteristics in Men With and Without
Ischemic Heart Disease
With IHD
(n 5 116)
Without IHD
(n 5 2,040)
Age (yr) 59 6 8* 56 6 7
Cigarette smoker (%) 43 34
$21/day (%) 32* 23
Ex-smoker (%) 37 37
Pipe or cigar smoker (%) 9 13
Diabetes mellitus (%) 4* 1
Systolic BP (mm Hg) 137 6 17* 130 6 17
Diastolic BP (mm Hg) 82 6 12 81 6 10
Lp(a) (mg/dl) 41.0 6 45.9* 32.7 6 34.9
Triglycerides (mmol/liter) 2.09 6 0.95 1.86 6 1.24
Total-C (mmol/liter) 6.08 6 1.06* 5.72 6 1.01
LDL-C (mmol/liter)† 4.19 6 0.96* 3.85 6 0.91
HDL-C (mmol/liter) 0.96 6 0.23* 1.01 6 0.26
Apo B (g/liter) 1.30 6 0.32* 1.17 6 0.31
*p , 0.05. †Since low density lipoprotein cholesterol (LDL-C) levels were
calculated: n 5 114 with and n 5 1,990 without ischemic heart disease (IHD).
Data presented are mean value 6 SD or percent of patients. Apo B 5
apoprotein B; BP 5 blood pressure; HDL-C 5 high density lipoprotein
cholesterol; Lp(a) 5 lipoprotein(a); Total-C 5 total cholesterol.
Table 2. Correlation of Lipoprotein(a) With Other Risk Factors
r Coeff p Value
Total-C 0.14 0.0001
LDL-C 0.15 0.0001
HDL-C 20.03 NS
Apo B 0.13 0.0001
Systolic BP 20.01 NS
Smoking status 0.01 NS
Coeff 5 coefficient; other abbreviations as in Table 1.
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the third tertile of the LDL cholesterol distribution is not
increased by the presence of elevated Lp(a). For HDL choles-
terol, the protective effect against IHD associated with the
third tertile of the distribution (Table 3) was lost when there
was a simultaneous elevation in Lp(a) (Table 5). There was a
significant increase in risk of IHD found in the second tertile of
the apoprotein B distribution if there was a concomitant
elevation of Lp(a) levels. However, the last tertile of the
apoprotein B distribution was associated with an increased risk
of IHD, and it appeared that the presence of elevated Lp(a)
further increased this risk (Table 5). For all these lipid risk
factors, the presence of Lp(a) levels $30 mg/dl in the first
tertile of the distribution was never associated with a signifi-
cant increase in risk of IHD.
Discussion
As expected, age, systolic blood pressure, smoking and
total, LDL and HDL cholesterol were significant independent
risk factors for a first IHD event in this cohort. The present
study indicated that elevated Lp(a) is not an independent risk
factor for a first IHD event in men, a finding that is also
supported by logarithmic and dichotomic manipulation of
Lp(a) data. However, there appears to be an interaction
between elevated Lp(a) concentration and total, LDL and
HDL cholesterol and apoprotein B levels.
Lp(a) and IHD. The differences between our study and
others regarding the contribution of Lp(a) as an independent
risk factor for IHD may most likely be the result of different
patients studied, experimental designs and technical ap-
proaches to the determination of Lp(a) levels. We used a
population-based prospective model in a primary prevention
setting, whereas most studies have been case-control or retro-
spective studies, with limited numbers of subjects. There were
also differences in end points. Most studies considered only MI
and coronary death as events, whereas we also included both
typical effort angina and coronary insufficiency with docu-
mented ECG ischemic changes along with MI and IHD death.
Nevertheless, when only MI and IHD death were considered,
Lp(a) was not a significant predictor in the present sample.
Table 3. Adjusted Risk Ratios for Ischemic Heart Disease According to Tertile of Risk Factors
Risk Factor
by Tertile Range
No. of
Pts
No. of
Events
Model 1*
[RR (95% CI)]
Model 2*
[RR (95% CI)]
Lp(a) (mg/dl)
1st tertile , 11 740 35 1.00 1.00
2nd tertile 11–33 710 39 1.13 (0.71–1.79) 1.12 (0.70–1.80)
3rd tertile . 33 706 42 1.17 (0.74–1.85) 1.16 (0.73–1.85)
Age (yr)
1st tertile 46–55 1,164 48 1.00 1.00
2nd tertile 56–65 755 40 1.17 (0.77–1.79) 1.11 (0.72–1.70)
3rd tertile $ 66 209 28 2.85 (1.74–4.67)† 2.68 (1.63–4.43)†
Systolic BP (mm Hg)
1st tertile , 122 720 20 1.00 1.00
2nd tertile 122–136 720 43 1.98 (1.15–3.39)† 2.14 (1.24–3.67)†
3rd tertile $ 137 716 53 2.32 (1.36–3.94)† 2.60 (1.52–4.42)†
Smoking status
Never smoked 333 12 1.00 1.00
Ex-smoker 790 43 1.04 (0.46–1.09) 1.09 (0.48–2.48)
Cigar/pipe 283 11 1.33 (0.59–2.97) 1.32 (0.59–2.96)
1–20 cig/day 245 13 1.45 (0.77–2.76) 1.49 (0.78–2.83)
$ 21 cig/day 505 37 2.47 (1.28–4.75)† 2.43 (1.26–4.68)†
Total-C (mmol/liter)
1st tertile , 5.22 720 26 1.00
2nd tertile 5.22–6.10 724 34 1.30 (0.78–2.17)
3rd tertile $ 6.11 712 56 2.15 (1.34–3.44)†
LDL-C (mmol/liter)
1st tertile , 3.47 700 23 1.00
2nd tertile 3.47–4.27 705 40 1.83 (1.09–3.07)†
3rd tertile $ 4.28 699 51 2.28 (1.38–3.75)†
HDL-C (mmol/liter)
1st tertile , 0.91 717 53 1.00
2nd tertile 0.91–1.11 717 37 0.71 (0.47–1.09)
3rd tertile $ 1.12 670 24 0.50 (0.30–0.81)†
*Lipoprotein(a) [Lp(a)], age, systolic blood pressure (BP) and smoking status were included in both models; in model
1, total cholesterol (Total-C) levels were also included; in model 2, total cholesterol was replaced by low density
lipoprotein (LDL-C) and high density lipoprotein cholesterol (HDL-C). CI 5 confidence interval; cig 5 cigarettes; RR 5
risk ratio. †p , 0.05 versus first tertile of risk factor distribution.
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Other studies have also failed to show a relation between Lp(a)
and IHD. For instance, a Finnish population-based prospec-
tive case-control study (22) could not find that Lp(a) was a risk
factor for MI. A nested case-control study of men from the
Helsinki Heart Study (2), also using MI as an end point, did
not find a relation between Lp(a) and MI. In contrast, there
are three population-based, prospective studies showing a
relation between Lp(a) and MI. The first (3), carried out in
Iceland, studied 1,332 men, 104 of whom had a fatal or
nonfatal MI (3). In that study, the event rate was roughly
threefold that found in our patients or in the Framingham
population (32), and cigarette smoking was not a predictor of
MI, which is at odds with most published reports. The second
study (GRIPS [19]) found a significant relation between fatal
and nonfatal MI and Lp(a). Men in the GRIPS trial, despite
their younger age, had relatively higher mean total and LDL
cholesterol levels than men in the present study. In the GRIPS
trial, LDL cholesterol was found to be the most important
predictor of MI, whereas elevated blood pressure and smoking
were not predictors of MI in multivariate models. This was not
the case for the present study, where age was the most
important risk factor, followed by systolic blood pressure,
smoking and LDL cholesterol. Finally, a recent study by the
Framingham group (20) in men 20 to 55 years old followed up
for 15 years used end points similar to ours. Once again, there
are striking differences between the reports. As would be
expected, when the age differences are considered, our event
rate is much higher than that found by Bostom et al. (20).
Furthermore, multivariate analyses that showed Lp(a) to be an
independent risk factor were done using a model that dichot-
omized risk factors, such as total LDL and HDL cholesterol.
These lipid values were dichomotized using lipid levels in
accordance with the National Cholesterol Education Program
(NCEP) (33) for men without IHD and with fewer than two
risk factors. Because of evidence that shows that the relation
between cholesterol and IHD risk is continuous (34) and a
recently published clinical trial (35) of lipid lowering that
shows that patients with so-called normal cholesterol levels
benefit from lipid-lowering therapy, we elected to treat lipid
values as continuous variables.
The GRIPS trial (19) also found an interaction between
elevated LDL cholesterol, Lp(a) and MI. Lp(a) may thus have
a predictive role for IHD in men with elevated LDL choles-
terol levels. However, our study shows that these results may
be attributable to a specific category of men with mildly
elevated LDL cholesterol levels. Furthermore, our study sug-
gests that elevated Lp(a) levels also enhance the risk associ-
ated with apoprotein B and total cholesterol. Although HDL
particles may not be directly related to Lp(a), the beneficial
effects associated with elevated HDL cholesterol levels were
lost in the presence of elevated Lp(a) levels. Thus, despite
significantly elevated levels in men with IHD, Lp(a) itself does
not increase the risk of IHD risk, but it may modulate other
risk factors in this male cohort prospectively followed up for 5
years. The results obtained with the second tertiles of LDL
cholesterol and apoprotein B distribution may seem contradic-
tory (Table 5). However, this contradiction could be a reflec-
tion of LDL particle size, which may be a better predictor of
IHD than LDL cholesterol or apoprotein B levels (36) in the
middle of their respective distributions.
Lp(a) measurement and storage. Also contributing to the
controversy of Lp(a) as a risk factor are the different ways in
which the samples are handled in different studies. There is a
lack of standardization of the measurement methods and
different assays (37) using various techniques (37,38). We
selected an ELISA-type assay because it appears that Lp(a)
measurements using such assays are not as affected by storage
(39) as other assays. The question of storage has been raised as
an explanation for the failure of studies to demonstrate an
effect of Lp(a). A recent study by Kronenberg et al. (40), also
using an ELISA-based Lp(a) assay (but different from the kit
that we used), suggested there was a decay in Lp(a) levels from
samples stored for ;2 years at 280°C. Their data, based on
310 frozen samples, suggest that there might be greater decay
in the samples with a higher content of lower molecular weight
Lp(a). Such lower molecular weight Lp(a) is usually found in
subjects with elevated Lp(a) concentrations. From these data
they extrapolated that after 8 years of storage under these
conditions, a difference of 9.6 mg/dl between groups would
disappear. If this were true, the Lp(a) distribution in our
cohort would not have been similar to that of other white
populations (16). Furthermore, the GRIPS trial was carried
out with the same Lp(a) assay that we used and has shown that
after 9 years of storage, Lp(a) levels are similar to those found
in fresh samples (17).
Lp(a) and atherosclerosis. A few mechanisms have been
proposed for the putative role of Lp(a) in IHD. Its incorpora-
tion into plaque and high affinity binding to glycosaminogly-
cans and fibronectin suggest a direct atherogenic action in
combination with elevated cholesterol (41). Our study brings
indirect confirmation of that hypothesis because Lp(a) could
Table 4. Significant Risk Factors in Stepwise Discriminant Analysis
of Risk Factors for Ischemic Heart Disease
Variable RR (95% CI) Chi-Square p Value
Model 1*
1. Age 1.05 (1.02–1.08) 19.436 0.0001
2. Total-C 1.01 (1.01–1.03) 15.327 0.0001
3. Systolic BP 1.02 (1.01–1.03) 8.027 0.0046
4. Smoking status 1.21 (1.06–1.37) 8.023 0.0046
5. Lp(a) 1.00 (1.00–1.00) 3.464 0.0627
Model 2*
1. Systolic BP 1.02 (1.01–1.07) 18.458 0.0001
2. LDL-C 1.01 (1.00–1.01) 12.436 0.0004
3. Age 1.05 (1.02–1.07) 10.465 0.0012
4. Smoking status 1.20 (1.05–1.36) 9.193 0.0024
5. HDL-C 0.97 (0.95–0.99) 6.813 0.0009
6. Lp(a) 1.00 (1.00–1.00) 3.068 0.798
*Lipoprotein(a) [Lp(a)], age, systolic blood pressure (BP) and smoking
status were included in both models; in model 1, total cholesterol (Total-C) levels
were also included; in model 2, total cholesterol was replaced by low density
lipoprotein (LDL-C) and high density lipoprotein cholesterol (HDL-C). Other
abbreviations as in Table 3.
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not be found to be independent of other risk factors. Lp(a) has
less resistance to oxidation than does the LDL particle (42,43)
and can be actively taken up by scavenger receptors, leading
to the formation of foam cells (44). Because of similarities
of apoprotein(a) to domains of plasminogen, Lp(a) may
impair fibrinolytic activity by competing with plasminogen
for fibrin binding, by competing with tissue-type plasmino-
gen activator for fibrin binding (45– 47) or by direct binding
to fibrin (41). Further studies are required to demonstrate a
synergistic mechanism between Lp(a) and other lipid frac-
tions.
Conclusions. Our data show that in this population-based,
prospective setting, Lp(a) is not an independent risk factor for
IHD but appears to increase the risk associated with other risk
factors. These findings have important clinical implications
because they suggest that Lp(a) measurements should not be
carried out in a primary prevention effort. It would appear that
Lp(a) measurements might be useful in patients with IHD with
other known risk factors, especially mildly elevated LDL
cholesterol. Also noteworthy was the finding that the beneficial
effects of elevated HDL cholesterol appeared to be lost in men
with elevated Lp(a), which suggests that Lp(a) determinations
may be useful in these men. The resistance of Lp(a) to
lowering suggests that intervention on the other risk factor
might be the appropriate therapeutic choice, a strategy that has
already been proven effective in a tertiary prevention setting
(48). This hypothesis will need to be substantiated by appro-
priate lipid-lowering trials.
Table 5. Interaction Between Lipoprotein(a) and Other Lipid Risk Factors for Ischemic Heart Disease
Risk Factor by
Tertile
No. of
Pts
No. of
Events
Risk Factor Level
(mean 6 SD)
Lp(a) (mg/dl)
(mean 6 SD) RR (95% CI)
Total-C (mmol/liter)
1st tertile
Low Lp(a) 496 16 4.63 6 0.44 11.5 6 8.1 1.00
High Lp(a) 215 10 4.71 6 0.47 63.3 6 27.4 1.45 (0.66–3.18)
2nd tertile
Low Lp(a) 445 23 5.69 6 0.26 12.0 6 7.8 1.61 (0.85–3.05)
High Lp(a) 269 11 5.74 6 0.26 72.2 6 34.2 1.26 (0.58–2.70)
3rd tertile
Low Lp(a) 418 30 6.83 6 0.65 12.4 6 8.4 2.19 (1.19–4.03)*
High Lp(a) 280 26 6.90 6 0.65 75.4 6 38.1 2.96 (1.59–5.51)*
LDL-C (mmol/liter)
1st tertile
Low Lp(a) 494 15 2.87 6 0.44 11.3 6 7.9 1.00
High Lp(a) 195 8 2.92 6 0.44 64.4 6 30.6 1.35 (0.57–3.17)
2nd tertile
Low Lp(a) 425 23 3.86 6 0.23 12.4 6 8.1 1.79 (0.94–3.44)
High Lp(a) 270 17 3.85 6 0.23 72.2 6 33.9 2.08 (1.04–4.16)*
3rd tertile
Low Lp(a) 402 30 4.86 6 0.52 12.4 6 8.1 2.43 (1.30–4.53)*
High Lp(a) 287 21 4.94 6 0.57 73.6 6 35.7 2.45 (1.26–4.76)*
HDL-C (mmol/liter)
1st tertile
Low Lp(a) 496 31 0.77 6 0.10 11.6 6 7.8 1.00
High Lp(a) 251 23 0.77 6 0.10 72.0 6 35.1 1.53 (0.89–2.64)
2nd tertile
Low Lp(a) 438 26 1.01 6 0.05 12.8 6 8.5 0.98 (0.58–1.66)
High Lp(a) 274 11 1.01 6 0.05 70.2 6 33.4 0.65 (0.33–1.30)
3rd tertile
Low Lp(a) 425 12 1.34 6 0.21 11.4 6 8.0 0.46 (0.24–0.90)*
High Lp(a) 239 13 1.29 6 0.16 70.6 6 34.5 0.89 (0.47–1.71)
Apo B (g/liter)
1st tertile
Low Lp(a) 506 15 0.85 6 0.13 11.4 6 8.1 1.00
High Lp(a) 210 6 0.86 6 0.14 63.7 6 29.8 0.95 (0.37–2.46)
2nd tertile
Low Lp(a) 436 27 1.17 6 0.74 12.3 6 8.0 2.02 (1.07–3.81)*
High Lp(a) 267 14 1.17 6 0.70 70.2 6 31.1 1.77 (0.85–3.66)
3rd tertile
Low Lp(a) 417 27 1.52 6 0.19 12.2 6 8.2 2.22 (1.18–4.17)*
High Lp(a) 287 27 1.52 6 0.21 76.8 6 39.0 3.24 (1.73–6.10)*
*p , 0.05 versus group of patients (Pts) in the first tertile of risk factor distribution and low lipoprotein(a) [Lp(a)]
levels. Other abbreviations as in Tables 1 and 3.
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